Literature DB >> 24768161

Prenatal drug exposure, behavioral problems, and drug experimentation among African-American urban adolescents.

Yan Wang1, Stacy Buckingham-Howes1, Prasanna Nair1, Shijun Zhu2, Laurence S Magder3, Maureen M Black4.   

Abstract

PURPOSE: To examine how prenatal drug exposure (PDE) to heroin/cocaine and behavioral problems relate to adolescent drug experimentation.
METHODS: The sample included African-American adolescents (mean age = 14.2 years, SD = 1.2) with PDE (n = 73) and a nonexposed community comparison (n = 61). PDE status was determined at delivery through toxicology analysis and maternal report. Internalizing/externalizing problems were assessed during adolescence with the Behavior Assessment System for Children, Second Edition. Drug experimentation was assessed by adolescent report and urine analysis. Logistic regression evaluated the likelihood of drug experimentation related to PDE and behavioral problems, adjusting for age, gender, PDE, perceived peer drug use, and caregiver drug use. Interaction terms examined gender modification.
RESULTS: Sixty-seven subjects (50%) used drugs: 25 (19%) used tobacco/alcohol only and 42 (31%) used marijuana/illegal drugs. Ninety-four subjects (70%) perceived peer drug use. PDE significantly increased the risk of tobacco/alcohol experimentation (odds ratio = 3.07, 95% confidence interval [CI] 1.09-8.66, p = .034) but not after covariate adjustment (adjusted odds ratio [aOR] = 1.16, 95% CI .31-4.33, p > .05). PDE was not related to the overall or marijuana/illegal drug experimentation. The likelihood of overall drug experimentation was doubled per SD increase in externalizing problems (aOR = 2.28, 95% CI 1.33-3.91, p = .003) and, among girls, 2.82 times greater (aOR = 2.82, 95% CI 1.34-5.94, p = .006) per SD increase in internalizing problems. Age and perceived peer drug use were significant covariates.
CONCLUSIONS: Drug experimentation was relatively common (50%), especially in the context of externalizing problems, internalizing problems (girls only), older age, and perceived peer drug use. Findings support the Problem Behavior Theory and suggest that adolescent drug prevention addresses behavioral problems and promotes prosocial peer groups.
Copyright © 2014 Society for Adolescent Health and Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Behavioral problems; Drug experimentation; Gender; Prenatal drug exposure

Mesh:

Year:  2014        PMID: 24768161      PMCID: PMC4752830          DOI: 10.1016/j.jadohealth.2014.02.021

Source DB:  PubMed          Journal:  J Adolesc Health        ISSN: 1054-139X            Impact factor:   5.012


  32 in total

1.  Early adolescent cocaine use as determined by hair analysis in a prenatal cocaine exposure cohort.

Authors:  Tamara Duckworth Warner; Marylou Behnke; Fonda Davis Eyler; Nancy J Szabo
Journal:  Neurotoxicol Teratol       Date:  2010-07-18       Impact factor: 3.763

2.  Age of onset of drug use and its association with DSM-IV drug abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey.

Authors:  B F Grant; D A Dawson
Journal:  J Subst Abuse       Date:  1998

3.  Predicting adolescent substance use: the effects of depressed mood and positive expectancies.

Authors:  Heddy Kovach Clark; Chris L Ringwalt; Stephen R Shamblen
Journal:  Addict Behav       Date:  2011-01-20       Impact factor: 3.913

4.  The effects of prenatal cocaine exposure on problem behavior in children 4-10 years.

Authors:  Sonia Minnes; Lynn T Singer; H Lester Kirchner; Elizabeth Short; Barbara Lewis; Sudtida Satayathum; Dyianweh Queh
Journal:  Neurotoxicol Teratol       Date:  2010-03-20       Impact factor: 3.763

5.  "Liking" and "wanting" linked to Reward Deficiency Syndrome (RDS): hypothesizing differential responsivity in brain reward circuitry.

Authors:  Kenneth Blum; Eliot Gardner; Marlene Oscar-Berman; Mark Gold
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

6.  An interactionist perspective on the socioeconomic context of human development.

Authors:  Rand D Conger; M Brent Donnellan
Journal:  Annu Rev Psychol       Date:  2007       Impact factor: 24.137

7.  Gender differences in the relationship of internalizing and externalizing psychopathology to alcohol dependence: likelihood, expression and course.

Authors:  Deborah A Dawson; Risë B Goldstein; Howard B Moss; Ting-Kai Li; Bridget F Grant
Journal:  Drug Alcohol Depend       Date:  2010-06-16       Impact factor: 4.492

8.  Prenatal cocaine exposure, gender, and adolescent stress response: a prospective longitudinal study.

Authors:  Tara M Chaplin; Matthew B Freiburger; Linda C Mayes; Rajita Sinha
Journal:  Neurotoxicol Teratol       Date:  2010-09-17       Impact factor: 3.763

9.  Prenatal exposure to tobacco and future nicotine dependence: population-based cohort study.

Authors:  Mina Rydell; Sven Cnattingius; Fredrik Granath; Cecilia Magnusson; Maria Rosaria Galanti
Journal:  Br J Psychiatry       Date:  2012-02-09       Impact factor: 9.319

Review 10.  Systematic review of prenatal cocaine exposure and adolescent development.

Authors:  Stacy Buckingham-Howes; Sarah Shafer Berger; Laura A Scaletti; Maureen M Black
Journal:  Pediatrics       Date:  2013-05-27       Impact factor: 7.124

View more
  3 in total

1.  Prenatal Drug Exposure and Adolescent Cortisol Reactivity: Association with Behavioral Concerns.

Authors:  Stacy Buckingham-Howes; Dayna Mazza; Yan Wang; Douglas A Granger; Maureen M Black
Journal:  J Dev Behav Pediatr       Date:  2016-09       Impact factor: 2.225

2.  Does prenatal cocaine exposure predict adolescent substance use?

Authors:  David S Bennett; Michael Lewis
Journal:  Neurotoxicol Teratol       Date:  2020-06-11       Impact factor: 3.763

3.  Risk and protective factors for whoonga use among adolescents in South Africa.

Authors:  Teresa DeAtley; Catherine Mathews; Dan J Stein; David Grelotti; Larry K Brown; Danielle Giovenco; Millicent Atujuna; William Beardslee; Caroline Kuo
Journal:  Addict Behav Rep       Date:  2020-04-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.